Biogen taps Danish biotech firm for collaboration on novel Lupus treatment

Biotech firm ISD Immunotech has entered into collaboration with US Biogen to develop the Danish firm's drug candidate for the autoimmune disease Lupus. If everything goes well, the drug can go on a market in 2028.

ISD Immunotech CEO Tara Heitner. Photo: Immunotech / PR

ISD Immunotech has joined forced with one of the biggest players in the pharmaceutical world, and they share an ambition to develop the Danish firm's drug candidate for the treatment of a variant of the autoimmune disease lupus.

US firm Biogen, whose revenue was at DKK 89.5bn (USD 14.3bn) in 2019, and which occupies more than 7,500 employees around the world, adds millions of kroner and professional expertise to ISD Immunotech, which spun out of research from Aarhus University in 2008.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles